Timosaponin-BII inhibits the up-regulation of BACE1 induced by Ferric Chloride in rat retina

BMC Complementary and Alternative Medicine

Kun Xiong¹  Hui Wang¹  Chun-Ling Fan¹  Dan Chen¹  Shuang Chen¹  Meng-Qi Zhang²  Pei Liu³  Lei Shang¹  Ju-Fang Huang¹ 

[1] Department of Anatomy and Neurobiology, School of Basic Medical Sciences, Central South University, Changsha, Hunan, 410013, China;Eight-year Clinical Medicine Doctor Program, Grade 2006, Central South University Xiangya School of Medicine, Changsha, Hunan, 410013, China;Five-year Medicine Program, Grade 2009, Central South University Xiangya School of Medicine, Changsha, Hunan, 410013, China

关键词: Aβ;    Retina;    BACE1;    Oxidative stress;    Timosaponin-BII;   

Others  :  1231532
DOI  :  10.1186/1472-6882-12-189

 received in 2012-06-29, accepted in 2012-10-18,  发布年份 2012

【 摘 要 】

Background

Our previous studies indicated that oxidative stress up-regulated the expression of β-amyloid precursor protein cleavage enzyme-1 (BACE1) in rat retina. Pharmacological reports have shown Timosaponin-BII, a purified extract originating from Chinese medical herb Rhizoma Anemarrhenae, is characterized as an antioxidant. Our present study aimed to determine whether Timosaponin-BII affected the expression of BACE1, β-amyloid precursor protein cleavage production of Aβ1-40 and β-C-terminal fragment (β-CTF) in rat retina, which were pre-treated with the oxidizing agent (solution of FeCl₃).

Results

Few distinctions of BACE1 distribution were observed among all groups (normal control group, model group, Timosaponin-BII treated and vehicle control groups). Rat retinas in model group and vehicle control group manifested an apparent up-regulation of BACE1 expression. Meanwhile, the level of malonaldehyde (MDA), Aβ1-40 and β-CTF were increased. However, when comparing with the vehicle control group, the retinas in Timosaponin-BII treated group showed significantly less BACE1 (p<0.05) and accumulated less Aβ1-40 or β-CTF (p<0.05). It also showed significantly decreased level of MDA (p<0.05) and prolonged partial thromboplastin time (p<0.05).

Conclusion

Our data suggested that Timosaponin-BII remarkably inhibited the up-regulation of BACE1 and reduced the over-production of β-CTF and Aβ in rat retina, which was induced by FeCl₃. The mechanism of Timosaponin-BII on BACE1 expression may be related to its antioxidant property.

【 授权许可】

   
2012 Huang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Attems J, Yamaguchi H, Saido TC, Thal DR: Capillary CAA and perivascular Abeta-deposition: two distinct features of Alzheimer's disease pathology. J Neurol Sci 2010, 299(1–2):155-162.
• [2]Gotz J, Eckert A, Matamales M, Ittner LM, Liu X: Modes of Abeta toxicity in Alzheimer's disease. Cellular and molecular life sciences: CMLS 2011, 68(20):3359-3375.
• [3]Selkoe DJ: Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann N Y Acad Sci 2000, 924:17-25.
• [4]Selkoe DJ: Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001, 81(2):741-766.
• [5]Blasko I, Beer R, Bigl M, Apelt J, Franz G, Rudzki D, Ransmayr G, Kampfl A, Schliebs R: Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer's disease beta-secretase (BACE-1). J Neural Transm 2004, 111(4):523-536.
• [6]Wen Y, Onyewuchi O, Yang S, Liu R, Simpkins JW: Increased beta-secretase activity and expression in rats following transient cerebral ischemia. Brain Res 2004, 1009(1–2):1-8.
• [7]Tong Y, Zhou W, Fung V, Christensen MA, Qing H, Sun X, Song W: Oxidative stress potentiates BACE1 gene expression and Abeta generation. J Neural Transm 2005, 112(3):455-469.
• [8]Velliquette RA, O'Connor T, Vassar R: Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. J Neurosci 2005, 25(47):10874-10883.
• [9]Sun X, He G, Qing H, Zhou W, Dobie F, Cai F, Staufenbiel M, Huang LE, Song W: Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci U S A 2006, 103(49):18727-18732.
• [10]Yan XX, Xiong K, Luo XG, Struble RG, Clough RW: beta-Secretase expression in normal and functionally deprived rat olfactory bulbs: inverse correlation with oxidative metabolic activity. J Comp Neurol 2007, 501(1):52-69.
• [11]Huang JF, Huang K, Shang L, Wang H, Yan XX, Xiong K: Beta-amyloid precursor protein cleavage enzyme-1 expression in adult rat retinal neurons in the early period after lead exposure. Neural Regen Res 2011, 6(14):1045-1051.
• [12]Xiong K, Cai H, Luo XG, Struble RG, Clough RW, Yan XX: Mitochondrial respiratory inhibition and oxidative stress elevate beta-secretase (BACE1) proteins and activity in vivo in the rat retina. Exp Brain Res 2007, 181(3):435-446.
• [13]Misonou H, Morishima-Kawashima M, Ihara Y: Oxidative stress induces intracellular accumulation of amyloid beta-protein (Abeta) in human neuroblastoma cells. Biochemistry 2000, 39(23):6951-6959.
• [14]Paola D, Domenicotti C, Nitti M, Vitali A, Borghi R, Cottalasso D, Zaccheo D, Odetti P, Strocchi P, Marinari UM, et al.: Oxidative stress induces increase in intracellular amyloid beta-protein production and selective activation of betaI and betaII PKCs in NT2 cells. Biochem Biophys Res Commun 2000, 268(2):642-646.
• [15]Tamagno E, Bardini P, Obbili A, Vitali A, Borghi R, Zaccheo D, Pronzato MA, Danni O, Smith MA, Perry G, et al.: Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis 2002, 10(3):279-288.
• [16]Fukumoto H, Cheung BS, Hyman BT, Irizarry MC: Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 2002, 59(9):1381-1389.
• [17]Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, Beach T, Sue L, Sabbagh M, Cai H, et al.: Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci U S A 2004, 101(10):3632-3637.
• [18]Ji X, Feng YF: Advances in studies on saponins in Anemarrhena asphodeloides. Chinese Traditional and Herbal Drugs 2010, 41(4):S12-S15.
• [19]Hu Y, Xia Z, Sun Q, Orsi A, Rees D: A new approach to the pharmacological regulation of memory: Sarsasapogenin improves memory by elevating the low muscarinic acetylcholine receptor density in brains of memory-deficit rat models. Brain Res 2005, 1060(1–2):26-39.
• [20]Li TJ, Qiu Y, Yang PY, Rui YC, Chen WS: Timosaponin B-II improves memory and learning dysfunction induced by cerebral ischemia in rats. Neurosci Lett 2007, 421(2):147-151.
• [21]Lu WQ, Qiu Y, Li TJ, Tao X, Sun LN, Chen WS: Timosaponin B-II inhibits pro-inflammatory cytokine induction by lipopolysaccharide in BV2 cells. Arch Pharm Res 2009, 32(9):1301-1308.
• [22]Ouyang S, Sun LS, Guo SL, Liu X, Xu JP: Effects of timosaponins on learning and memory abilities of rats with dementia induced by lateral cerebral ventricular injection of amyloid beta- peptide. Di Yi Jun Yi Da Xue Xue Bao 2005, 25(2):121-126.
• [23]Cai F, Sun L, Gao S, Yang Y, Yang Q, Chen W: A rapid and sensitive liquid chromatography-tandem mass spectrometric method for the determination of timosaponin B-II in blood plasma and a study of the pharmacokinetics of saponin in the rat. J Pharm Biomed Anal 2008, 48(5):1411-1416.
• [24]Lu WQ, Qiu Y, Li TJ, Tao X, Sun LN, Chen WS: Antiplatelet and antithrombotic activities of timosaponin B-II, an extract of Anemarrhena asphodeloides. Clin Exp Pharmacol Physiol 2011, 38(7):430-434.
• [25]Forstl H, Kurz A: Clinical features of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 1999, 249(6):288-290.
• [26]Backman L, Jones S, Berger AK, Laukka EJ, Small BJ: Multiple cognitive deficits during the transition to Alzheimer's disease. J Intern Med 2004, 256(3):195-204.
• [27]Frost S, Martins RN, Kanagasingam Y: Ocular biomarkers for early detection of Alzheimer's disease. J Alzheimers Dis 2010, 22(1):1-16.
• [28]Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, Miller CA, Ko MK, Black KL, Schwartz M, Farkas DL: Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. NeuroImage 2011, 54(Suppl 1):S204-S217.
• [29]Chiu K, Chan TF, Wu A, Leung IY, So KF, Chang RC: Neurodegeneration of the retina in mouse models of Alzheimer's disease: what can we learn from the retina? Age (Dordr) 2012, 34(3):633-649.
• [30]Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, et al.: Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001, 60(8):759-767.
• [31]Reed TT, Pierce WM, Markesbery WR, Butterfield DA: Proteomic identification of HNE-bound proteins in early Alzheimer disease: Insights into the role of lipid peroxidation in the progression of AD. Brain Res 2009, 1274:66-76.
• [32]Smith MA, Zhu X, Tabaton M, Liu G, McKeel DW Jr, Cohen ML, Wang X, Siedlak SL, Dwyer BE, Hayashi T, et al.: Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J Alzheimer's Disease: JAD 2010, 19(1):363-372.
• [33]Lee HP, Pancholi N, Esposito L, Previll LA, Wang X, Zhu X, Smith MA, Lee HG: Early induction of oxidative stress in mouse model of Alzheimer disease with reduced mitochondrial superoxide dismutase activity. PLoS One 2012, 7(1):e28033.
• [34]Butterfield DA, Sultana R: Methionine-35 of abeta(1–42): importance for oxidative stress in Alzheimer disease. J Amino Acids 2011, 2011:198430.
• [35]Ma B, Xu Q, Zhao Y, Xiong C, Tan D: Use of timosaponin Bll in the preparation of a medicament or product for the prevention and treatment of stroke. Google Patents 2011.
• [36]Yun D, Bai-ping M, Yu-wen C, Yu-xian S, Jing-jing Z, Yu-jun S: Protective effects of timosaponin BII on primary neurons against beta amyloid peptide 25–35. Chin Pharmacol Bull 2009, 25(2):244-247.